Glioblastoma
December 2017 Issue
 
 
 

Nearly every major medical breakthrough over the past 50 years can be attributed to new discoveries that were made possible through meticulous biomedical research. Many diseases and conditions that previously took a heavy toll on patients in terms of both morbidity and mortality are now either treatable or preventable thanks in large part to painstaking research that expanded the frontiers of scientific knowledge and moved the most promising basic research developments into tangible health benefits through human clinical trails. Ongoing research is also the key that will open the door to additional major medical advances and breakthroughs in the future.

Our staff at Medifocus is committed to keeping our subscribers to the Medifocus Digest Alert on Glioblastoma abreast of the latest new research developments that have recently been published in the medical literature for this condition. In this issue of the Digest Alert, you will find a focused list of hand-picked journal article references that represent the latest advances in basic and clinical research for Glioblastoma. These articles represent the current state-of-the-art of the research that will hopefully lead to additional major advances and breakthroughs in the clinical management of Glioblastoma. You can access the summaries of each article referenced below by simply clicking on the article Title.

We will continue to update you with the latest scientific and clinical developments through the Medifocus Digest Alert on Glioblastoma every 3 months. Thank you for your ongoing subscription to this publication.

Sincerely,
Elliot Jacob, Ph.D.
Vice-President - Content
Medifocus.com, Inc.



1:Lomustine and Bevacizumab in Progressive Glioblastoma.
Authors:Wick W, Gorlia T, Bendszus M, Taphoorn M, Sahm F, Harting I, Brandes AA, Taal W, Domont J, Idbaih A, Campone M, Clement PM, Stupp R, Fabbro M, Le Rhun E, Dubois F, Weller M, von Deimling A, Golfinopoulos V, Bromberg JC, Platten M, Klein M, van den Bent MJ
Institution:From the University Medical Center and German Cancer Research Center, Heidelberg, Germany (W.W., M.B., F.S., I.H., A.D., M.P.); the European Organization for Research and Treatment of Cancer, Brussels (T.G., V.G.), and Leuven Cancer Institute-KU Leuven, Leuven (P.M.C.) - both in Belgium; Haaglanden Medical Center, The Hague (M.T.), Erasmus MC Cancer Institute, Rotterdam (W.T., J.C.B., M.J.B.), and VU University Medical Center, Amsterdam (M.K.) - all in the Netherlands; the Medical Oncology Department, Azienda Unita Sanitaria Locale di Bologna-IRCCS Istituto delle Scienze Neurologiche, Bologna, Italy (A.A.B.); Institut Gustave Roussy, Villejuif (J.D.), Assistance Publique-Hopitaux de Paris, Hopitaux Universitaires La Pitie Salpetriere-Charles Foix, Service de Neurologie 2-Mazarin, INSERM Unite 1127, Centre National de la Recherche Scientifique Unite Mixte de Recherche (UMR) 7225, Sorbonne Universites, University Pierre and Marie Curie 06 UMR S1127, and Institut du Cerveau et de la Moelle Epiniere, Paris (A.I.), Institut de Cancerologie de l'Ouest-Centre Rene Gauducheau, Saint-Herblain (M.C.), Institut Regional du Cancer Montpellier, Montpellier (M.F.), and Centre Hospitalier Regional Universitaire de Lille, Lille (E.L.R., F.D.) - all in France; and the Departments of Oncology and Neurology, University Hospital and University of Zurich, Zurich, Switzerland (R.S., M.W.).
Journal:N Engl J Med. 2017 Nov 16;377(20):1954-1963. doi: 10.1056/NEJMoa1707358.

2:Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international study.
Authors:van den Bent M, Gan HK, Lassman AB, Kumthekar P, Merrell R, Butowski N, Lwin Z, Mikkelsen T, Nabors LB, Papadopoulos KP, Penas-Prado M, Simes J, Wheeler H, Walbert T, Scott AM, Gomez E, Lee HJ, Roberts-Rapp L, Xiong H, Bain E, Ansell PJ, Holen KD, Maag D, Reardon DA
Institution:Brain Tumor Center, Erasmus MC Cancer Institute, Groene Hilledijk 301, 3075 EA, Rotterdam, the Netherlands. m.vandenbent@erasmusmc.nl. University Medical Center, New York, NY, USA. Francisco, CA, USA. Royal Brisbane and Women's Hospital, Brisbane, Australia.
Journal:Cancer Chemother Pharmacol. 2017 Dec;80(6):1209-1217. doi: 10.1007/s00280-017-3451-1. Epub 2017 Oct 26.

3:Phase II study of bi-weekly temozolomide plus bevacizumab for adult patients with recurrent glioblastoma.
Authors:Badruddoja MA, Pazzi M, Sanan A, Schroeder K, Kuzma K, Norton T, Scully T, Mahadevan D, Ahmadi MM
Institution:Center for Neurosciences, 2450 E River Rd, Tucson, AZ, 85718, USA. badru001@neurotucson.com. Campbell Avenue, Tucson, AZ, 85724, USA. badru001@neurotucson.com.
Journal:Cancer Chemother Pharmacol. 2017 Oct;80(4):715-721. doi: 10.1007/s00280-017-3405-7. Epub 2017 Aug 14.

4:Challenges to Treating Older Glioblastoma Patients: the Influence of Clinical and Tumour Characteristics on Survival Outcomes.
Authors:Lorimer CF, Hanna C, Saran F, Chalmers A, Brock J
Institution:Brighton and Sussex Medical School, Brighton, UK. juliet.brock@bsuh.nhs.uk.
Journal:Clin Oncol (R Coll Radiol). 2017 Nov;29(11):739-747. doi: 10.1016/j.clon.2017.05.010. Epub 2017 Aug 12.

5:Short course radiotherapy concomitant with temozolomide in GBM patients: a phase II study.
Authors:Fariselli L, Cuppini L, Gaviani P, Marchetti M, Pinzi V, Milanesi I, Simonetti G, Tramacere I, DiMeco F, Salmaggi A, Silvani A
Institution:Neurosurgery Department, Radiotherapy Unit, IRCCS Fondazione Istituto Neurologico Carlo Besta, Milan - Italy. Carlo Besta, Milan - Italy. Neurologico Carlo Besta, Milan - Italy. Carlo Besta, Milan - Italy. Carlo Besta, Milan - Italy. Carlo Besta, Milan - Italy. Istituto Neurologico Carlo Besta, Milan - Italy. - Italy. - Italy. Neurologico Carlo Besta, Milan - Italy. Neurologico Carlo Besta, Milan - Italy.
Journal:Tumori. 2017 Sep 18;103(5):457-463. doi: 10.5301/tj.5000672. Epub 2017 Jul 8.

6:Adult Glioblastoma.
Authors:Alexander BM, Cloughesy TF
Institution:Brian M. Alexander, Dana-Farber/Brigham and Women's Cancer Center, Harvard Medical School, Boston, MA; and Timothy F. Cloughesy, University of California Los Angeles, Los Angeles, CA.
Journal:J Clin Oncol. 2017 Jul 20;35(21):2402-2409. doi: 10.1200/JCO.2017.73.0119. Epub 2017 Jun 22.

7:Survival Outcomes With Short-Course Radiation Therapy in Elderly Patients With Glioblastoma: Data From a Randomized Phase 3 Trial.
Authors:Guedes de Castro D, Matiello J, Roa W, Ghosh S, Kepka L, Kumar N, Sinaika V, Lomidze D, Hentati D, Rosenblatt E, Fidarova E
Institution:AC Camargo Cancer Center, Sao Paulo, Brazil. Electronic address: dougguedes@uol.com.br. Canada. Canada.
Journal:Int J Radiat Oncol Biol Phys. 2017 Jul 15;98(4):931-938. doi: 10.1016/j.ijrobp.2017.03.037. Epub 2017 Mar 30.

8:Management of Glioblastoma Multiforme in Elderly Patients: A Review of the Literature.
Authors:Halani SH, Babu R, Adamson DC
Institution:Department of Neurosurgery, Emory University School of Medicine, Atlanta, Georgia, USA. Medicine, Durham, North Carolina, USA. Georgia, USA; Neurosurgery Section, Atlanta VA Medical Center, Decatur, Georgia, USA. Electronic address: cory.adamson@emory.edu.
Journal:World Neurosurg. 2017 Sep;105:53-62. doi: 10.1016/j.wneu.2017.04.153. Epub 2017 Apr 30.

9:Angiogenesis inhibitors in tackling recurrent glioblastoma.
Authors:Hundsberger T, Reardon DA, Wen PY
Institution:a Department of Neurology and Department of Hematology /Oncology , Cantonal hospital , St. Gallen , Switzerland. Cancer Center , Boston , MA , USA. Cancer Center , Boston , MA , USA.
Journal:Expert Rev Anticancer Ther. 2017 Jun;17(6):507-515. doi: 10.1080/14737140.2017.1322903. Epub 2017 May 2.

10:Prognostic Implications of Extent of Resection in Glioblastoma: Analysis from a Large Database.
Authors:Trifiletti DM, Alonso C, Grover S, Fadul CE, Sheehan JP, Showalter TN
Institution:Department of Radiation Oncology, University of Virginia, Charlottesville, Virginia, USA. Electronic address: daniel.trifiletti@gmail.com. Virginia, USA. of Pennsylvania, Philadelphia, Pennsylvania, USA. Charlottesville, Virginia, USA; Department of Neurological Surgery, University of Virginia School of Medicine, Charlottesville, Virginia, USA. Virginia, USA; Department of Neurological Surgery, University of Virginia School of Medicine, Charlottesville, Virginia, USA. Virginia, USA.
Journal:World Neurosurg. 2017 Jul;103:330-340. doi: 10.1016/j.wneu.2017.04.035. Epub 2017 Apr 17.

11:Biomarkers and Immunotherapeutic Targets in Glioblastoma.
Authors:Hung AL, Garzon-Muvdi T, Lim M
Institution:Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. Baltimore, Maryland, USA. Baltimore, Maryland, USA. Electronic address: Mlim3@jhmi.edu.
Journal:World Neurosurg. 2017 Jun;102:494-506. doi: 10.1016/j.wneu.2017.03.011. Epub 2017 Mar 12.

12:Secondary Glioblastoma: Molecular and Clinical Factors That Affect Outcome After Malignant Progression of a Lower Grade Tumor.
Authors:Gessler F, Zappi J, Konczalla J, Bernstock JD, Forster MT, Wagner M, Mittelbronn M, Seifert V, Senft C
Institution:Department of Neurosurgery, University Hospital Frankfurt, Goethe-University, Frankfurt, Germany. Electronic address: f.gessler@med.uni-frankfurt.de. Frankfurt, Germany. Frankfurt, Germany. Institutes of Health (NINDS/NIH), Bethesda, Maryland, USA. Frankfurt, Germany. Frankfurt, Germany. Goethe-University, Frankfurt, Germany. Frankfurt, Germany. Frankfurt, Germany.
Journal:World Neurosurg. 2017 Jun;102:49-55. doi: 10.1016/j.wneu.2017.02.104. Epub 2017 Mar 2.

13:On glioblastoma and the search for a cure: where do we stand?
Authors:Bianco J, Bastiancich C, Jankovski A, des Rieux A, Preat V, Danhier F
Institution:Louvain Drug Research Institute, Advanced Drug Delivery and Biomaterials, Universite catholique de Louvain, Avenue Mounier 73, bte B1 73.12, 1200, Brussels, Belgium. john.bianco@uclouvain.be. Universite catholique de Louvain, Avenue Mounier 73, bte B1 73.12, 1200, Brussels, Belgium. B1.54.10, 1200, Brussels, Belgium. Belgium. Universite catholique de Louvain, Avenue Mounier 73, bte B1 73.12, 1200, Brussels, Belgium. 1348, Louvain-la-Neuve, Belgium. Universite catholique de Louvain, Avenue Mounier 73, bte B1 73.12, 1200, Brussels, Belgium. veronique.preat@uclouvain.be. Universite catholique de Louvain, Avenue Mounier 73, bte B1 73.12, 1200, Brussels, Belgium.
Journal:Cell Mol Life Sci. 2017 Jul;74(13):2451-2466. doi: 10.1007/s00018-017-2483-3. Epub 2017 Feb 17.

14:Temozolomide during radiotherapy of glioblastoma multiforme : Daily administration improves survival.
Authors:Nachbichler SB, Schupp G, Ballhausen H, Niyazi M, Belka C
Institution:Department of Radiation Oncology, LMU Munich, Marchioninistrasse 15, 81377, Munich, Germany. silke.nachbichler@med.uni-muenchen.de. Munich, Germany. Munich, Germany. Munich, Germany. Munich, Germany.
Journal:Strahlenther Onkol. 2017 Nov;193(11):890-896. doi: 10.1007/s00066-017-1110-4. Epub 2017 Feb 14.

15:Life beyond a diagnosis of glioblastoma: a systematic review of the literature.
Authors:Gately L, McLachlan SA, Dowling A, Philip J
Institution:Department of Medical Oncology, St Vincent's Hospital, Melbourne, Australia. lucyjgately@hotmail.com.
Journal:J Cancer Surviv. 2017 Aug;11(4):447-452. doi: 10.1007/s11764-017-0602-7. Epub 2017 Feb 13.

For a FREE PREVIEW of the Medifocus Guidebook on Glioblastoma click here

To purchase a copy of the COMPLETE Medifocus Guidebook on Glioblastoma click here

To subscribe to additional FREE Medifocus Digest Alert on other disease/condition areas click here

  
Get the Medifocus Guidebook on Glioblastoma...
at a Special 20% Discount


Medifocus Guidebook on Glioblastoma

Updated: June 21, 2017
192 Pages

This one of a kind Guidebook offers:

  • Answers to your critical health questions including the latest treatments, clinical trials, and expert research.
     
  • High Quality, Professional level information you can trust and understand culled from the latest peer-reviewed journals.
     
  • Timely, up to date content with free guidebook updates for 1 year.
     
  • A unique resource to find leading experts, institutions, and support organizations including contact information and hyperlinks.
     
  • Over 130,000 Guidebooks Sold
     
  • 100% Risk Free Money Back Guarantee



ORDER THE GUIDEBOOK

The Medifocus Guidebook on Glioblastoma is available in the following two convenient formats:

PRINTED GUIDEBOOK

Soft-cover book that is available for immediate shipping via either U.S. Priority Mail or International AirMail (outside the U.S.).

  • Regular List Price = $36.95
  • Less 20% Discount = - $7.40
  • Discounted Price = $29.55(excluding shipping & handling)

Order the Printed Guidebook

DIGITAL GUIDEBOOK

Available for immediate download as a PDF document.

  • Regular List Price = $27.95
  • Less 20% Discount = - $5.60
  • Discounted Price = $22.35

Order the Digital Guidebook



Order by Phone

Call Toll Free in the U.S.
1-800-965-3002

From Outside the U.S.
1-301-649-9300

You can also receive a 20% discount when you order your Guidebook by phone.

To receive your 20% discount, simply mention the Discount Coupon Code below to the customer service representative taking your order.

Discount Coupon Code for
Phone Orders

GL62739154

Coupon Expires: January 10, 2018



What Our Customers Are Saying...

"To be diagnosed with a glioblastoma is devastating news. The MediFocus Guidebook on Glioblastoma clearly explained medical terms and adopted a positive approach although not discounting the problems."
E.S.
London, England


"Your Guidebook was EXTREMELY helpful and full of valuable information. I was able to understand "doctor language" and sound educated myself. It was well worth the price."
D.S.
Fairview, Tennessee


"I had never heard of Glioblastoma until one of my relatives was diagnosed with it and was given a very pessimistic outlook. Your Guidebook provided me with the background and sources of additional information necessary to allow me to be of help to him as he decided on his treatment options."
R.W.R.
Pittsfield, Massachusetts



  
Medifocus Digest Alert is published monthly by Medifocus, Inc.
6810 Park Heights Avenue, Suite C5, Baltimore, MD 21215 USA
Copyright © 2013 Medifocus, Inc. All rights reserved.